Acarbose for Longevity: What the Evidence Says in 2025
A guide to acarbose as a longevity drug, covering its mechanism, ITP mouse data, human trial results, dosing, side effects, and how it compares with rapamycin, metformin, NR, and NMN.
Longevity Rx
37 source-based articles maintained by the HealthRX.com Editorial Team.
37articles
6topic areas covered
Jul 10, 2025latest review
Longevity Rx library
Showing 37 of 37 clinical reviews.
Are Senolytics Ready for General Use?
A breakdown of senolytics, rapamycin, metformin, and biological age testing for longevity, what the current trial data actually supports and what remains experimental.
Berberine for Longevity: What the Science Actually Shows in 2025
A breakdown of berberine's longevity evidence alongside rapamycin, metformin, NR, and NMN. Real trial data, doses, and clinical context.
Biological Aging: What It Is, How to Measure It, and What Actually Slows It
An evidence-based guide to biological aging, epigenetic clocks, functional measures, frailty, and interventions with human health or mobility outcomes.
Cellular Senescence: What It Is, Why It Drives Aging, and What Clinicians Can Do About It
A deep dive into cellular senescence, the biology of zombie cells, their role in frailty, sarcopenia, and mitochondrial dysfunction, plus the current evidence on senolytic and senomorphic interventions.
Cost of Compounded Rapamycin: 2025 Pricing, Insurance, and What to Expect
Compounded rapamycin for longevity typically costs $40, $150 per month out of pocket. Insurance rarely covers off-label use. Learn exact pricing tiers, pharmacy options, and how to verify legitimacy.
Cost of NMN Supplements in 2026: Prices, Compounded Rapamycin, and Insurance Reality
A detailed 2026 pricing guide for NMN supplements, compounded rapamycin, and other longevity-focused compounds, plus an honest look at what insurance will and will not cover for off-label use.
Does Metformin Extend Life in Non-Diabetics?
A clinical review of metformin for longevity in people without diabetes, plus where rapamycin, senolytics, and biological age testing actually stand in human evidence. Distinguishes FDA-approved use from off-label longevity use and observational data from trial data.
Does Rapamycin Really Extend Lifespan?
A clinical deep-dive into rapamycin, senolytics, metformin, and biological age testing for longevity. Evidence-based guidance on what works, what is experimental, and what healthy adults should know before taking any longevity drug.
Frailty Syndrome: Causes, Diagnosis, and Evidence-Based Treatment
A guide to frailty syndrome covering the Fried phenotype criteria, biological mechanisms including sarcopenia and mitochondrial dysfunction, and interventions supported by randomized trial data.
GLP-1s for Longevity: The Off-Label Science Behind Semaglutide, Rapamycin, Metformin, NR, and NMN
A deep dive into GLP-1 receptor agonists and four companion longevity drugs used off-label: rapamycin, metformin, nicotinamide riboside, and NMN. Covers mechanisms, trial data, doses, and candidacy criteria.
Glucosamine and Longevity: What the Evidence Actually Shows
A deep dive into glucosamine as a longevity compound, plus the most current evidence on rapamycin, metformin, nicotinamide riboside, and NMN for healthy aging.
Inflammaging: What Chronic Low-Grade Inflammation Does to Your Body and How to Slow It
Inflammaging is the chronic, low-grade inflammatory state that accelerates biological aging, drives cellular senescence, and raises the risk of cardiovascular disease, dementia, and frailty. Learn what the science says and what you can do about it.
Insurance Coverage for Off-Label Drug Use: What Patients Pay in 2025
A guide to insurance coverage for off-label drug use, including rapamycin, NMN, GLP-1s, and compounded therapies. Understand your appeal rights, real costs, and clinical strategies to reduce out-of-pocket spending.
Long-Term Metformin Safety: What the Evidence Actually Shows
A guide to long-term metformin safety, covering lactic acidosis risk, B12 depletion, kidney thresholds, rapamycin monitoring, and senolytic trial signals.
Longevity Protocols for Athletes: Performance, Recovery, and Healthy Aging After 40
A guide to longevity medicine for athletes over 40 and 50, covering TRT, GLP-1s, HGH peptides, HRT, cognitive protection, and dementia risk reduction backed by named trials and guidelines.
Longevity RX: The Evidence-Based Protocol for Living Longer and Healthier
A guide to the longevity interventions with the strongest clinical evidence, including GLP-1s, exercise, sleep, diet, biomarker testing, and hormone optimization.
Low Dose Lithium for Longevity: What the Science Actually Shows
A look at low-dose lithium, rapamycin, metformin, NR, and NMN as longevity agents. Covers mechanisms, doses, trial data, and safety considerations.
Metformin for Non-Diabetics Is Not a Longevity Drug Yet
Off-label metformin prescribing for healthy adults as an anti-aging intervention rests on thin human evidence. The HealthRX.com Medical Team argues that until TAME reports, prescribing should follow metabolic indications, not a generalized aging signal.
Metformin Off-Label for Longevity: What the Science Actually Says in 2025
A breakdown of metformin, rapamycin, NR, NMN, and glucosamine as off-label longevity agents. Covers mechanisms, the state of trial evidence, dosing ranges used in practice, risks, and how to talk to your doctor.
Mild Cognitive Decline: Causes, Diagnosis, and Evidence-Based Treatment Options
A guide to mild cognitive decline covering biological aging, cellular senescence, mitochondrial dysfunction, and frailty syndrome, with evidence-based interventions and dosing details.
Mitochondrial Dysfunction: What It Is, Why It Ages You Faster, and What Clinicians Can Do About It
Mitochondrial dysfunction drives biological aging, frailty, sarcopenia, and cellular senescence. Learn the mechanisms, biomarkers, and evidence-based interventions clinicians use to slow or partially reverse mitochondrial decline.
Nicotinamide Riboside (NR): Evidence, Dosing, and Longevity Applications
A deep-dive into nicotinamide riboside (NR): how it raises NAD+, what human trials show, how it compares to NMN, rapamycin, metformin, and glucosamine, and what doses are supported by current evidence.
NMN and NR Dosing: Evidence-Based Protocols for NAD+ Precursors, Rapamycin, and Metformin
A guide to NMN and NR dosing, weekly rapamycin protocols, and off-label metformin dosing for longevity, with trial data and specific dose ranges for each compound.
NMN Dosing and Evidence: What Clinicians Prescribe
NMN raises whole-blood NAD+ within 60 minutes at 500 mg, per a 2022 trial. Clinicians typically dose 250 to 500 mg daily. See the evidence and dosing details.
Off-Label Metformin Dosing for Longevity: Protocols, Evidence, and What Clinicians Actually Prescribe
A guide to off-label metformin dosing for longevity, covering evidence from TAME, ITP mouse data, rapamycin weekly protocols, and NMN/NR NAD+ precursor dosing, with inline citations to primary sources.
PEARL vs RAP-4 vs Earlier Human Rapamycin Trials: A Cross-Trial Comparison for Longevity
A rigorous side-by-side synthesis of PEARL (2024), RAP-4 (2025), Mannick 2018, and Kraig 2018 on rapamycin dosing, immune endpoints, biological-age proxies, and adverse effects in healthy aging adults.
Rapamycin (Sirolimus) for Longevity: What the Evidence Actually Shows
A guide to rapamycin, metformin, NR, NMN, and glucosamine as longevity interventions, mechanisms, trial data, doses, and clinical decision points.
Rapamycin Side Effects and Monitoring: What Patients and Clinicians Need to Know
A clinical deep-dive into rapamycin side effects, safety signals from senolytic and longevity trials, long-term metformin safety comparisons, and the lab monitoring schedule every off-label user needs.
Sarcopenia: Causes, Diagnosis, Treatment, and How to Slow Muscle Loss With Age
Sarcopenia is the age-related loss of skeletal muscle mass and strength that drives frailty, falls, and early death. Learn what causes it, how it is diagnosed, and which interventions actually work.
SGLT2 Inhibitors for Longevity: What the Evidence Says in 2025
A deep dive into whether SGLT2 inhibitors like empagliflozin and dapagliflozin extend healthspan, how they compare to rapamycin, metformin, NR, and NMN, and what the current evidence supports for off-label longevity use.
Should Healthy People Take Rapamycin?
A breakdown of whether healthy adults should use rapamycin for longevity, covering human trial data, dosing protocols, side-effect profiles, biological age testing, senolytics, and metformin as comparators.
Spermidine: The Autophagy-Activating Compound Behind Longevity Research
Spermidine triggers autophagy, reduces cardiovascular risk, and may extend healthspan. Learn the evidence-backed doses, food sources, and how it compares to rapamycin, metformin, NR, and NMN.
Those With Family History of Dementia: What the Evidence Says About Prevention, HRT, and Brain Health
If a parent or sibling had dementia, your risk is real but not fixed. This clinically reviewed guide covers genetic risk, the critical hormone timing window, lifestyle evidence, and actionable steps for adults over 50 with a family history of dementia.
Welche Senolytika sind sicher? Dasatinib, Quercetin, Navitoclax
Keine Senolytika haben Phase-3-Studien bestanden. Alle zeigten Nebenwirkungen, von Thrombozytopenie bis Magen-Darm-Beschwerden. Die Evidenzlage im Detail.
What Is Biological Age and Can You Measure It?
Biological age reflects how well your cells, organs, and epigenome are functioning, not how long you have been alive. Learn which tests measure it accurately, what the evidence says about slowing it, and which longevity drugs are ready for clinical use.
What Labs Predict Biological Age
A guide to the blood tests, epigenetic clocks, and organ-function panels that measure biological age, plus what is and is not established about rapamycin, metformin, and senolytics as interventions on those numbers.
